2009
DOI: 10.1021/ol902298s
|View full text |Cite
|
Sign up to set email alerts
|

Overcoming the Drug Resistance in Breast Cancer Cells by Rational Design of Efficient Glutathione S-Transferase Inhibitors

Abstract: A new type of competitive human GST inhibitors has been developed via the bioisostere and structure activity profile strategies; we report their discovery, preparation, inhibitory activity, and synergetic effect in combination with chemotherapy drugs against breast cancer cells.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2010
2010
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(10 citation statements)
references
References 26 publications
0
10
0
Order By: Relevance
“…Only GST-p expression has been investigated in relation to the radiotherapy response in breast cancer and head-and-neck cancer patients but no significance to response was observed (42,43). Inhibitors directed against GSTs have shown synergistic effects with chemotherapy drugs in breast cancer cell lines, some of which produce ROS as a byproduct of their action (44). A general GST inhibitor that has shown radiosensitization in the MCF-7 breast cancer cell line is ethacrynic acid, a well-known diuretic (45).…”
Section: Discussionmentioning
confidence: 99%
“…Only GST-p expression has been investigated in relation to the radiotherapy response in breast cancer and head-and-neck cancer patients but no significance to response was observed (42,43). Inhibitors directed against GSTs have shown synergistic effects with chemotherapy drugs in breast cancer cell lines, some of which produce ROS as a byproduct of their action (44). A general GST inhibitor that has shown radiosensitization in the MCF-7 breast cancer cell line is ethacrynic acid, a well-known diuretic (45).…”
Section: Discussionmentioning
confidence: 99%
“…Considerable effort has been expended in the development of GST (particularly GSTP) inhibitors, largely to overcome GST-dependent drug resistance (for reviews, see van Bladeren and van Ommen 1991; Tew et al 1997;Burg and Mulder 2002;Townsend and Tew 2003;Mahajan and Atkins 2005;Mathew et al 2006;Zhao and Wang 2006;Li et al 2010;Thurairatnam 2012;Wu and Batist 2013;Mohana and Achary 2017). Inhibitors of the several classes of cytosolic GSTs are discussed below.…”
Section: Inhibitorsmentioning
confidence: 99%
“…We have previously developed thiol conjugate addition DCLs directed towards GST inhibition, and successfully interfaced the enzyme with small molecules so that it controlled library evolution27. The GSTs are well suited to exploration using DCC methods, being well-characterized, robust proteins having nascent medicinal chemistry application46,47. There are relatively few ligands reported in the literature for GST binding—a plus point, as it would enable us to use DCC as a genuine discovery tool for new binding motifs, rather than as a proof-of-principle process for confirming the binding ability of known ligands.…”
mentioning
confidence: 99%